English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/78794
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

ABCB1_3435C>T polymorphism and pharmacoresistance of epilepsy: differences related with the etiology of epilepsy

AuthorsSánchez, M. Blanca; Herranz, José L.; Leno, Carlos; Arteaga, Rosa; Oterino, Agustín; Valdizán, Elsa M. ; Nicolás, José M.; Peralta, G.; Adin, Javier; Blanco-Ramos, I.; Armijo, Juan A.
Issue Date2009
PublisherJohn Wiley & Sons
CitationEuropean Journal of Neurology 16(s3): 475 (2009)
AbstractThe etiology of epilepsy is a factor associated with differences in response to anticonvulsants and control of epilepsy. The aim of this study was to analyze the association between ABCB1_3435C>T and ABCB1_2677G>T polymorphisms and pharmacoresistance in patients stratified by epilepsy etiology. Caucasian epileptic patients (n=289) attending Neuropaediatrics and Neurology Services at the Marqués de Valdecilla University Hospital were selected when they had either drug resistance (occurrence of at least four seizures over the year before recruitment with trials of more than three appropriate antiepileptic drugs at appropriate dosages) or drug responsiveness (complete freedom from seizures for at least a year). Samples were genotyped by Applied Biosystems Genotyping Assays with TaqMan probes. Association was evaluated by stratified bivariate analysis using contingency tables. A significant association was found between ABCB1_3435C>T polymorphism and pharmacoresistance in symptomatic epilepsies (n=69, p=0.008), but not in idiopathic (n=97) or in cryptogenic (n= 123) ones. Patients with ABCB1_3435TT genotype had a lower risk of pharmacoresistance than those with ABCB1_CC genotype in symptomatic epilepsies (OR: 0.20, 95%CI: 0.07-0.58). In contrast, the risk was higher in idiopathic epilepsies (OR: 11.0, 95%CI: 1.1-106.8). The interaction between the etiology and the polymorphism was significant (p=0.002). Pharmacoresistance risk in patients with ABCB1_2677TT genotype was also lower than in those with ABCB1_2677CC genotype in symptomatic epilepsies and higher in idiopathic epilepsies but ORs were not significant. ABCB1_3435TT genotype is associated with a lower risk of pharmacoresistance than ABCB1_3435CC genotype in patients with symptomatic epilepsies, but not in idiopathic or cryptogenic epilepsies.
DescriptionTrabajo presentado al 13th Congress of the EFNS celebrado en Florencia del 12 al 15 de septiembre de 2009.
Identifiersissn: 1351-5101
e-issn: 1468-1331
Appears in Collections:(IBBTEC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.